KM Research Hub
← 返回论文库
已完成 入排:符合 图源:可得 入排置信度 0.98

STELLAR: Phase III, Randomized, Open-Label Study of Eflornithine Plus Lomustine Versus Lomustine Alone in Patients With Recurrent Grade 3 Astrocytoma.

Howard Colman, Giuseppe Lombardi, Eric T Wong, Tobias Walbert, Marica Eoli, Andrew B Lassman, David M Peereboom, Sani H Kizilbash, Carlos Kamiya-Matsuoka, Marshall W Pitz, Roy E Strowd, Annick Desjardins, Priya Kumthekar, Warren Mason, Alessia Pellerino, Riccardo Soffietti, Nicholas Butowski, Peter A Forsyth, Mohamed A Hamza, Peter Hau, Enrico Lallana, Burt Nabors, David Piccioni, Erik J Uhlmann, Liam C Welsh, Patrick Y Wen, Jorg Dietrich, Chao Wang, Victor A Levin

J Clin Oncol 44(8) 641-652

PMID41325560
PMCIDPMC12959603
DOI10.1200/JCO-25-01204
发表日期2025-12-01
入排依据:原始人体肿瘤 Phase III 随机药物试验,并报告 time-to-event 疗效结局。
图像/No. at risk 复核:KM 曲线已提取;No. at risk 信息待人工复核,不影响当前曲线图像显示。
摘要

摘要

PURPOSE: STELLAR (ClinicalTrials.gov identifier: NCT02796261) was a phase III, randomized, open-label trial of eflornithine + lomustine versus lomustine monotherapy in patients with recurrent grade 3 astrocytoma. METHODS: At trial initiation, eligibility criteria included: age ≥18 years, anaplastic astrocytoma (2016 WHO CNS Tumor classification [WHO CNS4]), first recurrence ≥6 months after radiation and temozolomide (TMZ), Karnofsky performance status ≥70, and no imaging findings consistent with grade 4 glioblastoma. Random assignment (1:1) was stratified by isocitrate dehydrogenase (IDH) mutation, age, resection extent, and geography. Patients received eflornithine (2.8 g/m2 orally, every 8 hours [2 weeks on, 1 week off]) + lomustine (90 mg/m2 orally, once every 6 weeks), or lomustine monotherapy (110 mg/m2 once every 6 weeks). The primary end point was overall survival (OS). RESULTS: Among 343 patients randomly assigned across 74 sites in eight countries, there was no difference in survival between eflornithine + lomustine and lomustine monotherapy (median OS 23.4 v 20.3 months, hazard ratio [HR], 0.94). Following changes in classification and grading in the 2021 WHO CNS5, a subset analysis of patients with IDH-mutant, grade 3 astrocytoma (n = 196), defined in 2024, before unblinding, showed clinically meaningful improvements in median OS with eflornithine + lomustine versus lomustine monotherapy (34.9 v 23.5 months, HR, 0.64) and median progression-free survival (PFS, 15.8 v 7.2 months, HR, 0.57). No differences were observed among patients with CNS grade 4 disease. Grade ≥3 treatment-emergent adverse events of relevance were related to reversible myelosuppression (eflornithine + lomustine 42% v lomustine monotherapy 29% of patients) and hearing impairment (24% v 0%). No new safety signals were identified. CONCLUSION: Clinically meaningful improvements were observed; eflornithine + lomustine doubled PFS and improved OS in patients with recurrent IDH-mutant, grade 3 astrocytoma, but not grade 4 tumors, after prior radiotherapy and TMZ, consistent with its cytostatic mechanism of action.

KM 提取结果

2 个 Figure · 4 个 KM 面板

进入结果中心
KM Figure2 个面板

FIG 2.

FIG 2. Kaplan-Meier curves of OS for the (A) ITT population and (B) IDH -mut grade 3 subset (investigator assessment by treatment). P values are from the log-rank test stratified by age (≤45 v > 45) and number of prior surgeries. For the ITT population P value was also stratified by IDH status (mutant v wild-type). CDKN2A/B , cyclin-dependent kinase inhibitor 2A/B ; IDH -mut, isocitrate dehydrogenase mutation; ITT, intention-to-treat; N, total number of patients; OS, overall survival.

A

overall survival

FIG 2. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

overall survival

FIG 2. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 2. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
KM Figure2 个面板

FIG 3.

FIG 3. Kaplan-Meier curves of PFS for the (A) ITT population and (B) IDH -mut grade 3 subset (investigator assessment by treatment). P values are from the log-rank test stratified by age (≤45 v > 45) and number of prior surgeries. For the ITT population P value was also stratified by IDH status (mutant v wild-type). CDKN2A/B , cyclin-dependent kinase inhibitor 2A/B ; IDH -mut, isocitrate dehydrogenase mutation; ITT, intention-to-treat; N, total number of patients; PFS, progression-free survival.

A

PFS

FIG 3. · Panel A

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel A 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
B

PFS

FIG 3. · Panel B

complete 待 EXE 对齐 预期 2 条 已提取 2 条

Panel B 是同一 FIG 3. 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。

查看结果
其他 Figure(5,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIG 1.FIG 1. CONSORT diagram (ITT population and IDH -mut grade 3 subset). a ITT: Eflornithine + lomustine, deaths by EOS (n = 129). b ITT: Lomustine monotherapy, deaths by EOS (n = 128). c Never treated: the most common reason was due to the open-label nature of the study, larger numbers of patients withdrew in the lomustine monotherapy arm as they did not want to be treated with lomustine only. d Includes: patient with kidney stones (lomustine); patient diffusion capacity of carbon monoxide was too low and was not eligible for trial; patient did not wait/never received the study drug; patient died while on treatment. e IDH-mut grade 3 without CDKN2A/B subset, eflornithine + lomustine, deaths by EOS (n = 59). f IDH-mut grade 3 without CDKN2A/B subset, lomustine monotherapy, deaths by EOS (n = 72). CDKN2A/B , cyclin-dependent kinase inhibitor 2A/B ; IDH , isocitrate dehydrogenase ; IDH -mut, IDH mutation; ITT, intention-to-treat population; N, total number of patients.
非 KM Figure
FIG A1.FIG A1. WHO CNS Tumor Reclassification of grade 3 astrocytoma from 2016 (CNS4) to 2021 (CNS5): STELLAR. STELLAR began enrolling patients in September 2016 on the basis of the 2016 WHO CNS4 criteria and completed enrollment of 343 patients in January 2022. When the 2021 WHO CNS5 was published in August 2021, STELLAR had already enrolled 333 patients, and thus, the study was at 98% of its enrollment target. The statistical analysis plan was proactively amended before unblinding to evaluate the impact of tumor molecular characteristics on OS and PFS, including homozygous deletion status of CDKN2A/B . This allowed analysis of patients with different disease types enrolled in STELLAR study using the updated 2021 WHO CNS5. All patients enrolled in STELLAR had disease that progressed or recurred after irradiation and TMZ chemotherapy. a The large majority of IDH -wt astrocytoma histologically grade 2 or 3 tumors are reclassified to grade 4, as defined by molecular features. b IDH -wt is diagnosed in the setting of an IDH -wt diffuse and astrocytic glioma in adults if there is microvascular proliferation or necrosis or TERT promoter mutation or EGFR gene amplification or +7/-10 chromosome copy number change. CDKN2A/B, cyclin-dependent kinase inhibitor 2A/B; EGFR, epidermal growth factor receptor ; IDH, isocitrate dehydrogenase; IDH -mut, IDH mutation; IDH-wt, IDH -wild-type; PFS, progression-free survival; OS, overall survival; TERT, telomerase reverse transcriptase ; TMZ, temozolomide.
非 KM Figure
FIG A2.FIG A2. STELLAR study design. a Initial lomustine dose was 110 mg/m 2 . Following a preplanned safety analysis, the dose of lomustine was reduced after five patients experienced grade 4 thrombocytopenia.
非 KM Figure
FIG A3.FIG A3. Bayesian analysis: Forest plot for OS HRs by subgroup (ITT; IDH- mut grade 3; IDH- wt and IDH- mut). Parameters were estimated using the simple contrast comparing eflornithine + lomustine with lomustine monotherapy from the Cox model with treatment, subgroup, and treatment-by-subgroup interaction terms. Bayesian shrinkage analysis assumed a noninformative prior distribution for the parameters, such that the HR estimated from the posterior distribution is more conservative. The degree of shrinkage indicates how much of the HR estimate is due to random variation. HR, hazard ratio; IDH -mut, IDH mutation; IDH -wt, IDH -wild-type; ITT, intent-to-treat; N, total number of patients; OS, overall survival.
非 KM Figure
FIG A4.FIG A4. Bayesian analysis: forest plot for PFS HRs by subgroup (ITT; IDH- mut grade 3; IDH- wt and IDH- mut). Parameters were estimated using the simple contrast comparing eflornithine + lomustine with lomustine monotherapy from the Cox model with treatment, subgroup, and treatment-by-subgroup interaction terms. Bayesian shrinkage analysis assumed a noninformative prior distribution for the parameters, such that the HR estimated from the posterior distribution is more conservative. The degree of shrinkage indicates how much of the HR estimate is due to random variation. HR, hazard ratio; IDH -mut, IDH mutation; IDH -wt, IDH -wild-type; ITT, intent-to-treat, N, total number of patients; PFS, progression-free survival.
非 KM Figure